Saatvik Green Energy旗下子公司獲得7.13億印度盧比的太陽能組件訂單

Mizuho Downgrades Adobe to Neutral From Outperform, Adjusts Price Target to $270 From $315

Adobe (ADBE) has an average rating of overweight and mean price target of $321.05, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)

US Treasury Yields Edge Up Pre-Bell as Iran's Hormuz Offer Delinks Deal With Nuclear Talks

Organon Agrees to Be Acquired by Sun Pharmaceutical in $11.75 Billion Deal

Organon (OGN) shares spiked early Monday after the healthcare company agreed to be acquired by Indian pharmaceutical firm Sun Pharmaceutical Industries in an all-cash deal with an enterprise value of about $11.75 billion.Shareholders of Organon will receive $14 a share in cash under the terms of the transaction, the companies said in a joint statement on Sunday. Organon's stock jumped 15% in the most recent premarket activity."Following a comprehensive review of strategic alternatives, our board determined that this all-cash transaction offers compelling and immediate value to Organon stockholders," Organon Chief Executive Carrie Cox said in the statement. "We believe Sun Pharma is well positioned to support Organon's businesses, employees and patients globally."Organon, which focuses on women's health, was formed in 2021 following its separation from pharmaceutical giant Merck (MRK).The deal, which requires approval from regulators and clearance from Organon's shareholders, is expected to complete early next year."This transaction is a logical next step in strengthening Sun Pharma's global business," according to Sun Pharma Managing Director Kirti Ganorkar. "In addition, there is a scope for synergies including significant revenue upside opportunities to be realized over the coming years."Sun Pharma intends to fund the acquisition through a combination of available cash resources and committed financing from banks. The Indian company anticipates the transaction to allow it to enter the biosimilar market.For the year ended Dec. 31, Organon reported revenue of $6.22 billion and adjusted earnings before interest, taxes, depreciation and amortization of $1.91 billion. In February, the company said it expected revenue of $6.2 billion for the current year, while five analysts polled by FactSet estimate $6.15 billion.